Applications of micro/nano drug delivery systems in cancer pain management.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 41625491.
- Also identified by DOI 10.1016/j.bioactmat.2026.01.013 and PMC identifier 12859437.
- Licence recorded as CC BY-NC-ND.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Cancer pain, a critical complication associated with advanced malignant tumors, significantly diminishes patients' quality of life and complicates therapeutic management due to its multifactorial pathophysiology. Current clinical analgesics often face limitations such as tolerance, addiction, and dose-dependent systemic toxicity. In contrast, micro/nano drug delivery systems (MNDDs) have emerged as promising strategies for managing cancer pain, owing to their unique advantages in precise targeting, including tumor-selective and neuropathic pain pathway targeting, controlled release, and multi-modal synergistic therapeutic effects. This review comprehensively examines the pathophysiological mechanisms underlying cancer pain, critically analyzes the pharmacological constraints and clinical limitations of existing analgesic regimens, and summarizes recent advances in engineered MNDDs. Additionally, we discuss the translational potential of multifunctional MNDDs, offering a multidisciplinary perspective to advance the development of precision-engineered, toxicity-minimized analgesic interventions.